STEM CELL THERAPY IN CANCER TREATMENT,CORNEAL TREATMENTS ETC...

1. BY
A.KABA FATHUM
M.SC (BIOCHEMISTRY)
VVV COLLEGE FOR WOMEN
VIRUDHUNAGAR

2. STEM CELLS
 STEM CELLS ARE THEMASTER CELLS.
THE REW MATERIAL –FROM WHICH ALL OF
 THE BODY CELLS MATURE .
THEY GIVE RISE TO BRAIN CELLS,PANCREATIC
CELLS,HEART CELLS ETC.
PROPERTIES............
 UNDIFFERENTIATE OR UNSPECIALIZED CELLS.
HAVING SELF RENEWAL PROPERTY.

3. TYPES OF STEM CELLS..............
 EMBRYONIC –DERIVED FROM THE INNER CELL
MASS OF A BLATOCYST.
 ADULT -DERIVED FROM MATURE ORGANISM
LIKE IN CORNEA,KIDNEY,ETC
 FETAL - DRIVED FROM ABORTED FETAL TISSUE.
 UMBLICAL - DRIVED FROM UMBLICAL CORDS.

4. STEM CELL
THERAPY...............
 STEM CELL THERAPY IS THE INTRODUCTION OF
NEW ADULT STEM CELL INTO DAMAGED TISSUE
IN ORDER TO TREAT DISEASE OR INJUIRY.
 THEY ARE USED TO CURE MANY DISEASE SUCH
AS;
ALZHEIMER’S DISEASE,HEART -DISEASE,ETC........

8. CORNEAL DISEASE

9. CANCER

10.  Human iPSC technology potentially can be used for
screening new cancer drugs and ultimately for providing
cells for transplant to treat a variety of diseases, including
cancer (yellow box). Genetic mutations can be corrected in
patient-derived iPSCs by gene targeting approaches. The
main hurdles to using patient-specific iPSCs for disease
modeling, drug screening, and transplantation purposes
are (i) a lack of effective differentiation protocols, (ii) little
or no engraftment capability for the majority of human
iPSC-derived specialized cells, (iii) difficulties in modeling
multifactorial diseases, (iv) the need for GMP-compliant
conditions at each step, and (v) safety concerns regarding
the potential tumorigenicity of iPSCs associated with their
pluripotent state or with insertional- or culture-driven
mutagenesis.

12. HEART DAMAGE